London, UK
Beth Israel Deaconess Medical Center, Boston
Sun 17
Persistent AR activity in enzalutamide resistant prostate cancer?
Beth Israel Deaconess Medical Center, Boston
London, UK
Peter MacCallum Cancer Centre, Melbourne
Wed 20
Estrogen receptor positive luminal progenitors the cancer cell of origin for estrogen receptor positive breast cancer
Peter MacCallum Cancer Centre, Melbourne
University of Adelaide / SAHMRI, Adelaide
Wed 20
Membrane lipid remodelling: untapped opportunities to predict and disrupt metastasis of hormone-dependent cancers
University of Adelaide / SAHMRI, Adelaide
Garvan Institute of Medical Research, Sydney
Sun 17
Mechanisms underlying uncontrolled genome doubling in breast cancer
Garvan Institute of Medical Research, Sydney
Wed 20
Mechanisms underlying uncontrolled genome doubling in breast cancer
Garvan Institute of Medical Research, Sydney
Garvan Institute of Medical Research, Sydney
Sun 17
Targeting stromal remodelling and cancer stem cell plasticity overcomes chemoresistance in metastatic triple negative breast cancer
Garvan Institute of Medical Research, Sydney
Garvan Institute of Medical Research, Sydney
Wed 20
Cancer cell plasticity drives the development of chemoresistance in breast cancer
Garvan Institute of Medical Research, Sydney
Royal College of Surgeons in Ireland, Dublin
Sun 17
Epi-transcriptomic alterations in ER-positive breast cancer
Royal College of Surgeons in Ireland, Dublin
KU Leuven University, Leuven
Walter and Eliza Hall Institute, Melbourne
Wed 20
Combinatorial co-targeting by miRNAs: a subtle but strong regulator of epithelial-mesenchymal transitions
Walter and Eliza Hall Institute, Melbourne
University of Minnesota, Minneapolis
Mon 18
Endocrine uncoupling: When androgen receptors are no longer receptors
University of Minnesota, Minneapolis
University of Otago, Dunedin
Institut de Biologica y Medicina Experimental, Buenos Aires
Wed 20
My name is ErbB-2, I will be called a transcription factor
Institut de Biologica y Medicina Experimental, Buenos Aires
Dana Farber Cancer Institute, Boston
Mon 18
Exploiting RB1 deficiency for novel therapeutic targets in prostate cancer
Dana Farber Cancer Institute, Boston
University of California, San Francisco
Sun 17
Basal vs luminal molecular subtyping in breast and prostate cancer: Implications for treatment selection
University of California, San Francisco
Menzies Institute for Medical Research, Hobart
Sun 17
Array comparative genomic hybridisation of familial prostate cancer tumours identifies a recurrent copy number gain on chr19p13.3 encompassing the EEF2 gene
Menzies Institute for Medical Research, Hobart
Peter MacCallum Cancer Centre, Melbourne
Sun 17
Estrogen receptor alpha controls gene expression via translational offsetting
Peter MacCallum Cancer Centre, Melbourne
McGill University, Montreal
Wed 20
The AR/mTOR/DNA-PK nuclear complexes: the missing links in prostate cancer?
McGill University, Montreal
University of California, San Francisco
University of Chicago, Chicago
Sun 17
Unexpected therapeutic efficacy of a SERM in mutant ER breast cancer
University of Chicago, Chicago
Centre for Cancer Biology, Adelaide
Wed 20
Estrogen receptor regulated miR-342 suppresses a pro-metastatic gene network
Centre for Cancer Biology, Adelaide
Fred Hutchinson Cancer Research Centre, Seattle
Mon 18
Profiling whole cancer genomes from circulating tumor DNA
Fred Hutchinson Cancer Research Centre, Seattle
University of Toronto, Toronto
Mon 18
Transcriptomic and functional landscape of circular RNA in prostate and breast cancer
University of Toronto, Toronto
DRMCRL, Adelaide
Institute of Health and Biomedical Innovation QUT, Brisbane
Tue 19
Convergence of regenerative medicine principles to develop new breast and prostate cancer mice models
Institute of Health and Biomedical Innovation QUT, Brisbane
University of Bordeaux, Bordeaux
Tue 19
What I cannot create, I do not understand: are MIND models the answer?
University of Bordeaux, Bordeaux
Dana Farber Cancer Institute, Boston
Mon 18
Endocrine resistance: The most common clinical mechanism
Dana Farber Cancer Institute, Boston
H3 Biomedicine Inc, Cambridge MA
University of Kentucky, Lexington
Mon 18
Androgen interference with prostate cancer response to Cabazitaxel
University of Kentucky, Lexington
Monash University, Melbourne
Sun 17
New combination therapies for castration-resistant prostate cancer
Monash University, Melbourne
UPMC, Pittsburgh
QIMR Berghofer, Brisbane
Walter and Eliza Hall Institute, Melbourne
Tue 19
Targeting cell survival pathways in breast cancer using BH3 mimetics
Walter and Eliza Hall Institute, Melbourne
Imperial College London, London
Mon 18
Endocrine resistance – common mechanisms? Not really. To each its own, a single cell tale of resistance
Imperial College London, London
UQ Centre for Clinical Research, Brisbane
Sun 17
Duke University School of Medicine, Durham
Oxford University / Queen's University of Belfast, Oxford
Wed 20
Contributions of the unfolded protein response and glycosylation to homeostasis
Oxford University / Queen's University of Belfast, Oxford
Fred Hutchinson Cancer Research Centre, Seattle
Wed 20
Intrinsic and extrinsic drivers of micro- and macro-metastasis
Fred Hutchinson Cancer Research Centre, Seattle
Garvan Institute of Medical Research, Sydney
Sun 17
Flicking the switch off, targeting MCL-1 in the treatment of breast and prostate cancer
Garvan Institute of Medical Research, Sydney
Garvan Institute of Medical Research, Sydney
Tue 19
A novel biomimetic tissue engineering platform to understand molecular mechanisms of drug resistance at single cell resolution
Garvan Institute of Medical Research, Sydney
University of Pittsburgh, Pittsburgh
Sun 17
Estrogen receptor alterations - the most frequent cause of death from breast cancer?
University of Pittsburgh, Pittsburgh
University of Liverpool, Liverpool
Mon 18
Immunotherapy for breast cancer: challenges and opportunities
University of Liverpool, Liverpool
La Trobe Institute for Molecular Science, Melbourne
Mon 18
Reversing tumour invisibility in bone to combat metastatic disease
La Trobe Institute for Molecular Science, Melbourne
Baruch S Blumberg Institute, Philadelphia
Wed 20
DACH1 gene deletion extends portraits of human prostate cancer
Baruch S Blumberg Institute, Philadelphia
USC Norris Comprehensive Cancer Center, Los Angeles
Mon 18
Role of tumor blood vessels and response to check point inhibitors
USC Norris Comprehensive Cancer Center, Los Angeles
UT Southwestern Medical Centre, Dallas
Sun 17
Overcoming endocrine resistance: masterminds, metaphors and mutants
UT Southwestern Medical Centre, Dallas
CRUK, Cambridge
Peter MacCallum Cancer Centre, Melbourne
Mon 18
Immunotherapy in prostate cancer: challenges and progress
Peter MacCallum Cancer Centre, Melbourne
University of Colorado, Denver
DRMCRL, Adelaide
DRMCRL, Adelaide
VHIO - Vall Hebron Institute of Oncology, Barcelona
Tue 19
Challenges and opportunities using ER-positive patient-derived tumour xenoimplant models
VHIO - Vall Hebron Institute of Oncology, Barcelona
CRUK, Cambridge
Mater Research Institute, Brisbane
Fred Hutchinson Cancer Research Centre, Seattle
Sun 17
Genetic susceptibility and risk stratification for prostate cancer screening and prevention
Fred Hutchinson Cancer Research Centre, Seattle
Garvan Institute of Medical Research, Sydney
Mon 18
Multi-dimensional single cell analysis of the tumour microenvironment
Garvan Institute of Medical Research, Sydney
Broad Institute, Boston
Walter and Eliza Hall Institute, Melbourne
Mon 18
Dissecting intraclonal plasticity during breast oncogenesis
Walter and Eliza Hall Institute, Melbourne
Royal College of Surgeons in Ireland, Dublin
Wed 20
Understanding the transcriptomic circulatory – blocking the rabbit holes early
Royal College of Surgeons in Ireland, Dublin
University of British Columbia, Vancouver
Mon 18
Cell plasticity in treatment resistant prostate cancer
University of British Columbia, Vancouver
Amsterdam, The Netherlands
Mon 18
Cistromics in clinical trials: Mechanistic insights in tumorigenesis and disease progression?
Amsterdam, The Netherlands
Workshop
0
Oral
0
Expert
0
Plenary
0
Catering and Social
0
Nurse
0
Other
0
Symposium
0
No Session Type
37
Sun 17
Genetic susceptibility and risk stratification for prostate cancer screening and prevention
Fred Hutchinson Cancer Research Centre, Seattle
Sun 17
Basal vs luminal molecular subtyping in breast and prostate cancer: Implications for treatment selection
University of California, San Francisco
Sun 17
Estrogen receptor alterations - the most frequent cause of death from breast cancer?
University of Pittsburgh, Pittsburgh
Sun 17
Overcoming endocrine resistance: masterminds, metaphors and mutants
UT Southwestern Medical Centre, Dallas
Sun 17
Persistent AR activity in enzalutamide resistant prostate cancer?
Beth Israel Deaconess Medical Center, Boston
Sun 17
Unexpected therapeutic efficacy of a SERM in mutant ER breast cancer
University of Chicago, Chicago
Sun 17
Mechanisms underlying uncontrolled genome doubling in breast cancer
Garvan Institute of Medical Research, Sydney
Sun 17
Targeting stromal remodelling and cancer stem cell plasticity overcomes chemoresistance in metastatic triple negative breast cancer
Garvan Institute of Medical Research, Sydney
Sun 17
Epi-transcriptomic alterations in ER-positive breast cancer
Royal College of Surgeons in Ireland, Dublin
Sun 17
Array comparative genomic hybridisation of familial prostate cancer tumours identifies a recurrent copy number gain on chr19p13.3 encompassing the EEF2 gene
Menzies Institute for Medical Research, Hobart
Sun 17
Estrogen receptor alpha controls gene expression via translational offsetting
Peter MacCallum Cancer Centre, Melbourne
Sun 17
New combination therapies for castration-resistant prostate cancer
Monash University, Melbourne
Sun 17
Sun 17
Flicking the switch off, targeting MCL-1 in the treatment of breast and prostate cancer
Garvan Institute of Medical Research, Sydney
Mon 18
Endocrine resistance: The most common clinical mechanism
Dana Farber Cancer Institute, Boston
Mon 18
Endocrine resistance – common mechanisms? Not really. To each its own, a single cell tale of resistance
Imperial College London, London
Mon 18
Endocrine uncoupling: When androgen receptors are no longer receptors
University of Minnesota, Minneapolis
Mon 18
Transcriptomic and functional landscape of circular RNA in prostate and breast cancer
University of Toronto, Toronto
Mon 18
Profiling whole cancer genomes from circulating tumor DNA
Fred Hutchinson Cancer Research Centre, Seattle
Mon 18
Cistromics in clinical trials: Mechanistic insights in tumorigenesis and disease progression?
Amsterdam, The Netherlands
Mon 18
Multi-dimensional single cell analysis of the tumour microenvironment
Garvan Institute of Medical Research, Sydney
Mon 18
Exploiting RB1 deficiency for novel therapeutic targets in prostate cancer
Dana Farber Cancer Institute, Boston
Mon 18
Cell plasticity in treatment resistant prostate cancer
University of British Columbia, Vancouver
Mon 18
Androgen interference with prostate cancer response to Cabazitaxel
University of Kentucky, Lexington
Mon 18
Dissecting intraclonal plasticity during breast oncogenesis
Walter and Eliza Hall Institute, Melbourne
Mon 18
Immunotherapy in prostate cancer: challenges and progress
Peter MacCallum Cancer Centre, Melbourne
Mon 18
Reversing tumour invisibility in bone to combat metastatic disease
La Trobe Institute for Molecular Science, Melbourne
Mon 18
Role of tumor blood vessels and response to check point inhibitors
USC Norris Comprehensive Cancer Center, Los Angeles
Mon 18
Immunotherapy for breast cancer: challenges and opportunities
University of Liverpool, Liverpool
Tue 19
Targeting cell survival pathways in breast cancer using BH3 mimetics
Walter and Eliza Hall Institute, Melbourne
Tue 19
A novel biomimetic tissue engineering platform to understand molecular mechanisms of drug resistance at single cell resolution
Garvan Institute of Medical Research, Sydney
Tue 19
What I cannot create, I do not understand: are MIND models the answer?
University of Bordeaux, Bordeaux
Tue 19
Challenges and opportunities using ER-positive patient-derived tumour xenoimplant models
VHIO - Vall Hebron Institute of Oncology, Barcelona
Tue 19
Convergence of regenerative medicine principles to develop new breast and prostate cancer mice models
Institute of Health and Biomedical Innovation QUT, Brisbane
Wed 20
DACH1 gene deletion extends portraits of human prostate cancer
Baruch S Blumberg Institute, Philadelphia
Wed 20
My name is ErbB-2, I will be called a transcription factor
Institut de Biologica y Medicina Experimental, Buenos Aires
Wed 20
Contributions of the unfolded protein response and glycosylation to homeostasis
Oxford University / Queen's University of Belfast, Oxford
Wed 20
Membrane lipid remodelling: untapped opportunities to predict and disrupt metastasis of hormone-dependent cancers
University of Adelaide / SAHMRI, Adelaide
Wed 20
The AR/mTOR/DNA-PK nuclear complexes: the missing links in prostate cancer?
McGill University, Montreal
Wed 20
Understanding the transcriptomic circulatory – blocking the rabbit holes early
Royal College of Surgeons in Ireland, Dublin
Wed 20
Intrinsic and extrinsic drivers of micro- and macro-metastasis
Fred Hutchinson Cancer Research Centre, Seattle
Wed 20
Cancer cell plasticity drives the development of chemoresistance in breast cancer
Garvan Institute of Medical Research, Sydney
Wed 20
Estrogen receptor positive luminal progenitors the cancer cell of origin for estrogen receptor positive breast cancer
Peter MacCallum Cancer Centre, Melbourne
Wed 20
Mechanisms underlying uncontrolled genome doubling in breast cancer
Garvan Institute of Medical Research, Sydney
Wed 20
Combinatorial co-targeting by miRNAs: a subtle but strong regulator of epithelial-mesenchymal transitions
Walter and Eliza Hall Institute, Melbourne
Wed 20
Estrogen receptor regulated miR-342 suppresses a pro-metastatic gene network
Centre for Cancer Biology, Adelaide
0 result(s) found.